From Matt Fleming <[email protected]>
Subject Read: Medicaid 'Fix' Will Worsen 340B Crisis
Date May 14, 2025 10:04 PM
  Links have been removed from this email. Learn more in the FAQ.
  Links have been removed from this email. Learn more in the FAQ.
View this email in your browser ([link removed])
[link removed]
A Most Flawed Notion: Medicaid 'Fix' Would Worsen 340B Crisis
Forbes | May 7, 2025 | Sally C. Pipes

Congressional Republicans are under pressure to find savings to make the math in their budget reconciliation package add up.

Medicaid, which accounts for just under 10% of federal spending, has become an obvious target. But instead of addressing the flawed incentives driving the program’s unsustainability, the Trump administration is pushing for a “most favored nation,” or MFN, policy on drug pricing…

This isn’t reform. It’s a gimmick.
Read here . . . ([link removed])
Is Era Of Biomedical Innovation Wins Against Cancer Over?
Newsmax | Sally C. Pipes | May 9, 2025

For evidence of the astounding progress made by medical science in recent decades, look no further than the Annual Report to the Nation on the Status of Cancer, which was jointly issued by the American Cancer Society, the Centers for Disease Control and Prevention, the North American Association of Central Cancer Registries, and the National Cancer Institute late last month.

Death rates from the disease have fallen steadily since the beginning of this century.

Between 2018 and 2022, they declined 1.5% per year.
Read more... ([link removed])

------------------------------------------------------------

Direct-To-Consumer Ozempic Sales Are A Win For Patients And Drug Makers
Forbes | Sally C. Pipes | May 12, 202

Google Wegovy. Or Zepbound. The search results offer a preview of a direct-to-consumer future for prescription drugs.

The brand-name drugs’ homepages generally get top billing. But not far down are ads for telehealth companies promising access to the drugs or others with the same active pharmaceutical ingredient, or API, without the need for an in-person visit or insurance.

These GLP-1 drugs have proven effective at helping people lose weight—and are showing promise for a host of other indications, including heart disease and liver disease. Making it easier for people to access them is a good thing for public health.
Read more... ([link removed])

[link removed]

============================================================
** Twitter ([link removed])
** Facebook ([link removed])
** YouTube ([link removed])
** LinkedIn ([link removed])
** Instagram ([link removed])
** Website ([link removed])
Copyright © 2024 *Pacific Research Institute*, All rights reserved.
You are receiving this email because you opted in via our website.

Our mailing address is:
P.O. Box 60485 Pasadena, CA 91116

** ([link removed])

Want to change how you receive these emails?
You can ** update your preferences ([link removed])
or ** unsubscribe from this list ([link removed])
.
Screenshot of the email generated on import

Message Analysis

  • Sender: n/a
  • Political Party: n/a
  • Country: n/a
  • State/Locality: n/a
  • Office: n/a
  • Email Providers:
    • MailChimp